No, Signos is not "FDA approved," but its app is FDA-cleared, which is a different thing. On March 21, 2025, the FDA cleared the Signos Glucose Monitoring System through a 510(k) (number K250106). That's the app that reads a Dexcom Stelo sensor. The GLP-1 medicines in the Signos+ program are compounded, and Signos itself says compounded GLP-1s are not FDA-approved.
So there are three separate answers, depending on which part of Signos you mean: the app (FDA-cleared), the Stelo sensor it uses (FDA-cleared in 2024) and the Signos+ medication (compounded, not FDA-approved). Below: what each one means, what the clearance does and doesn't say about weight loss, and how Signos+ compares with FDA-approved GLP-1 options.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
RX Index Decision Verdict: Signos's app and sensor went through a real FDA review, so "FDA-cleared" on its site is accurate. But clearance isn't approval, the cleared use is glucose tracking for people not on insulin, and the Signos+ GLP-1 medicines are compounded and not FDA-approved. Best fit for Signos: adults not on insulin who want to see their glucose response to food and exercise while they work on weight, with or without a GLP-1. Look elsewhere if: you want an FDA-approved weight-loss drug, you use insulin, or you've had problematic low blood sugar.
Signos FDA status at a glance
| Part of Signos | What it is | FDA status | FDA record |
|---|---|---|---|
| Signos Glucose Monitoring System | The Signos app that receives and analyzes CGM readings | Cleared through 510(k), March 21, 2025 (Class II, over the counter) | 510(k) K250106 |
| Dexcom Stelo sensor | The 15-day wearable glucose sensor Signos ships | Cleared March 5, 2024 as the first over-the-counter CGM | FDA announcement |
| Signos+ GLP-1 medicines | Compounded semaglutide and compounded tirzepatide, prescribed by clinicians through OpenLoop Health | Not FDA-approved (compounded) | Signos's own Signos+ FAQ |
| Signos CGM and GLP-1 Essentials plans | Sensors plus the app; no medication | Use the cleared app and sensor | Same as above |
FDA records checked November 19, 2026. Signos details come from Signos's plans and Signos+ pages, checked the same day.
If the glucose-tracking side is what interests you, Signos's plans page lists what each plan includes and what it costs right now.
See Signos plans and what's included (sponsored affiliate link, opens in a new tab)
Not sure yet? The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance, whether you want FDA-approved or compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool can show you which path fits before you choose.
FDA-cleared vs FDA-approved: why the word matters
The FDA uses two different words for two different reviews.
- Cleared means a device went through a 510(k) premarket notification. The maker shows the FDA that its device is "substantially equivalent" to a device that's already legally on the market, called a predicate. Most moderate-risk (Class II) devices, including over-the-counter glucose monitors, reach the market this way.
- Approved is the word for drugs, and for the highest-risk devices that go through premarket approval (PMA). A new drug, like Wegovy or Zepbound, gets approved only after the FDA reviews clinical trial evidence that it's safe and effective for a specific use.
Signos's app was cleared, not approved. That's normal for this kind of product and it's not a knock on Signos. It just means the claim to look for is "FDA-cleared," and that's the claim Signos makes on its own site.
Some coverage blurred the two words. The CNBC story Signos links from its homepage has a web address that reads "fda-approves-signos-glucose-monitoring-for-weight-loss". The FDA record itself says the decision was "Substantially Equivalent," which is a clearance.
What the FDA actually cleared Signos to do
The FDA clears a device for a stated "indication for use." Here's the Signos indication, word for word from the FDA decision summary:
"The Signos Glucose Monitoring System is an over-the-counter (OTC) mobile device application that receives data from an integrated Continuous Glucose Monitor (iCGM) sensor and is intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Signos System helps to identify normal (euglycemic) and low or high (dysglycemic) glucose levels. The Signos System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursions. This information may be useful in helping users to maintain a healthy weight. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional."
Read closely, that tells you four things:
- It's for adults not on insulin. If you use insulin, this isn't the device for you.
- It's a glucose display and analysis tool. The cleared job is measuring, recording and showing glucose, plus helping you see how food and exercise move it.
- The weight wording is soft. The FDA text says the information "may be useful in helping users to maintain a healthy weight." That's not the same as a drug label that reports trial weight loss.
- Don't change medicines based on it. Talk with a clinician before acting on a reading, especially if you take diabetes medicines.
The FDA record also lists the predicate device: Dexcom's Stelo Glucose Biosensor System (K234070). Signos's app shows the same 70 to 250 mg/dL glucose range as Stelo.
What clearance does not tell you
Clearance doesn't mean the FDA reviewed trial data showing Signos makes people lose a set amount of weight. Signos is running its own long study, registered as NCT05121844. It started in November 2021, lists about 31,000 people as its estimated enrollment and was marked "active, not recruiting" when we checked on November 19, 2026. We didn't find posted results.
Signos's marketing also makes claims like "87% report success in their first month" and "2x more likely to maintain weight loss at 12 months." Those are Signos's own claims. They aren't part of the FDA clearance. Signos footnotes the 87% figure to internal member data, and the Signos+ page we read didn't link a study for either.
The Stelo sensor: also cleared, with limits
Signos plans ship Dexcom's Stelo sensor. The FDA cleared Stelo on March 5, 2024 as the first CGM you can buy without a prescription.
What the FDA said about Stelo:
- It's for people 18 and older who don't use insulin.
- It's not for people with problematic hypoglycemia (low blood sugar), because it isn't designed to alert you to that.
- Each sensor can be worn up to 15 days.
- Readings and trends show up every 15 minutes in the app.
- Users shouldn't make medical decisions from it without talking to a health care provider.
Signos's own footnote says a study found 77.9% of sensors lasted the full 15 days. So about 1 in 5 may stop early.
Before you check out, Signos asks you to confirm that you're 18 or older, don't have problematic hypoglycemia, aren't on dialysis, aren't on insulin and don't have an active eating disorder.
Signos+ GLP-1s are compounded, and that's a different FDA story
Signos+ is the plan that adds a GLP-1 prescription to the sensor and app. Here, the FDA status flips. Signos says plainly on its Signos+ page: "All Signos+ medications are compounded; compounded GLP-1s are not FDA-approved."
What that means:
- A compounded drug is made by a pharmacy, not by the company that makes the brand-name drug.
- The FDA says compounded drugs are not FDA approved, and the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed."
- The FDA also says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug."
- Trial results on Wegovy's or Zepbound's labels don't tell you what a compounded version will do.
Signos says clinicians in its partner network, OpenLoop Health, review your intake and decide whether you get compounded semaglutide or compounded tirzepatide, and at what dose. Signos+ is offered in 49 states and DC, not Louisiana, which Signos says is because of state rules on compounded medicines. Ages 18 to 74 can apply (19 and up in Nebraska). In Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia, Signos says you'll do a video visit.
So "FDA-cleared" on a Signos+ box is true of the sensor and app inside it. It isn't true of the medicine.
What each Signos plan costs, and the FDA status of what you get
| Plan | Price on Signos's plans page (Nov 19, 2026) | What you get | FDA status of what's in it |
|---|---|---|---|
| Signos CGM, 6 months | $136/mo, shown as a sale from $169 | 2 sensors a month plus the app; ships in 3-month bundles; renews every 6 months | Cleared app and sensor |
| Signos CGM, 3 months | $160/mo, shown as a sale from $199 | Same, 3-month term | Cleared app and sensor |
| Signos CGM, 1 month | $240/mo, shown as a sale from $299 | Same, 1-month term | Cleared app and sensor |
| GLP-1 Essentials | $72/mo, shown as a sale from $89 | Six 15-day sensors over six months plus the app; for people already on a GLP-1; medication not included | Cleared app and sensor |
| Signos+ | Starting at $199/mo | 3- or 6-month compounded GLP-1 plan, sensors and the app | App and sensor cleared; medicine compounded, not FDA-approved |
The CGM plans page says "All sales final. No refunds or exchanges." Signos also says HSA and FSA eligibility depends on your plan administrator, and that its cancellation terms still apply if your plan won't reimburse you. Prices change often, so confirm on Signos's plans page before you buy.
Signos+ vs FDA-approved and other cash GLP-1 options
If your main goal is a GLP-1 prescription, here's how Signos+ stacks up on the FDA question against other programs The RX Index covers.
| Program | Medicine | FDA status of the medicine | Posted starting price (checked Nov 19, 2026) | Includes a CGM? |
|---|---|---|---|---|
| Signos+ | Compounded semaglutide or tirzepatide | Not FDA-approved | From $199/mo, 3- or 6-month plan | Yes, Stelo sensors and app |
| Ro | Brand-name Wegovy pill and pen, Zepbound, Foundayo pill and others | FDA-approved brand-name drugs | Membership $39 first month, then as low as $74/mo prepaid yearly; Wegovy pill or Foundayo pill first dose $149/mo | No |
| Arbor | Compounded semaglutide or tirzepatide | Not FDA-approved | $89/mo semaglutide or $119/mo tirzepatide on a 12-month prepaid plan (labeled Black Friday pricing); $179 or $249 month to month | No |
| Collective | Compounded semaglutide or tirzepatide | Not FDA-approved | $59/mo or $69/mo, plus $199/yr membership | No |
Signos+ is the only one of these with a glucose sensor built in. Ro is the only one here selling FDA-approved brand-name drugs. For more on that trade, see compounded vs name-brand GLP-1s and how to get an FDA-approved GLP-1.
If an FDA-approved drug is the priority, Ro is the option in this table that sells one.
See Ro's FDA-approved GLP-1 pricing (sponsored affiliate link, opens in a new tab)
Is Signos legit?
On the regulatory side, yes. The app has a real FDA clearance you can look up (K250106), and the Stelo sensor it uses has its own. Signos describes the cleared indication accurately on its site, including the "not on insulin" limit.
Where to stay careful:
- "FDA-cleared" covers the device, not the GLP-1. Signos says so itself, but it's easy to miss on a page that leads with "FDA-Cleared CGM."
- Weight-loss results aren't part of the clearance. The cleared text says glucose information "may be useful" for maintaining a healthy weight. Results claims on Signos's site are its own.
- CGM plans are final sale. Pick the plan length you'll actually use.
- Sensors can fail early. By Signos's own numbers, about 22% may not last the full 15 days.
Who Signos fits, and who should skip it
Signos fits if you:
- Are 18 or older and don't use insulin
- Want to see how meals, sleep and exercise move your glucose while you work on weight
- Already take a GLP-1 and want sensor data alongside it (GLP-1 Essentials)
- Want a compounded GLP-1 and a CGM in one plan, and you're comfortable with compounded medicine (Signos+)
Skip Signos, or ask your doctor first, if you:
- Use insulin, or have had problematic low blood sugar
- Want an FDA-approved weight-loss drug, which Signos+ doesn't offer
- Live in Louisiana and want Signos+
- Want to use insurance for the medicine
If the sensor-and-app route fits what you're after, the next step is picking a plan length on Signos's site.
Compare Signos plans for yourself (sponsored affiliate link, opens in a new tab)
If you're still weighing compounded vs FDA-approved, The RX Index's Find My GLP-1 Path tool can sort it out with a few quick questions.
Frequently asked questions
Is Signos FDA approved?
No. The Signos app is FDA-cleared, not FDA-approved. The FDA cleared the Signos Glucose Monitoring System through a 510(k) on March 21, 2025 (K250106). "Approved" is the word the FDA uses for drugs and for the highest-risk devices.
Is the Signos CGM FDA-cleared?
Yes. The Signos app is cleared (K250106), and the Dexcom Stelo sensor Signos ships was cleared on March 5, 2024 as the first over-the-counter CGM.
Is Signos FDA-cleared for weight loss?
Not as a weight-loss treatment. The cleared indication is measuring and displaying glucose in adults not on insulin and helping users see how diet and exercise affect it. The FDA text adds that this information "may be useful in helping users to maintain a healthy weight."
Are Signos+ GLP-1 medicines FDA-approved?
No. Signos says all Signos+ medicines are compounded semaglutide or tirzepatide, and that compounded GLP-1s are not FDA-approved.
Can I use Signos if I take insulin?
No. Both the Signos clearance and the Stelo clearance are for people 18 and older who are not on insulin.
Do I need a prescription for Signos?
Not for the CGM plans. The Signos system and the Stelo sensor are cleared for over-the-counter use. Signos+ includes a prescription, so a licensed clinician has to approve you first.
Does Signos take insurance?
Signos's pages say no insurance or prescription is needed for the CGM plans. HSA or FSA payment may work, but it depends on your plan administrator.
Has Signos published a weight-loss study?
Signos's long-term study, NCT05121844, was listed as "active, not recruiting" when we checked on November 19, 2026. We didn't find posted results on ClinicalTrials.gov.
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz. It takes about 2 minutes, with no signup.
Sources
- FDA 510(k) database: Signos Glucose Monitoring System, K250106 (decision date March 21, 2025; checked November 19, 2026)
- FDA clearance letter for K250106 (dated March 21, 2025; checked November 19, 2026)
- FDA 510(k) decision summary for K250106, including indications for use (checked November 19, 2026)
- FDA: Premarket Notification 510(k) (checked November 19, 2026)
- FDA: FDA Clears First Over-the-Counter Continuous Glucose Monitor, March 5, 2024 (checked November 19, 2026)
- FDA: concerns with unapproved GLP-1 drugs used for weight loss (checked November 19, 2026)
- ClinicalTrials.gov: NCT05121844, sponsored by Signos Inc (checked November 19, 2026)
- CNBC: Signos coverage, August 20, 2025 (checked November 19, 2026)
- Signos: homepage, plans and CGM plan prices (checked November 19, 2026)
- Signos: Signos+ program page and FAQ (checked November 19, 2026)
- Ro: Ro Body membership and GLP-1 pricing (checked November 19, 2026)
- Arbor: homepage and FAQ pricing (checked November 19, 2026)
- Collective: homepage pricing (checked November 19, 2026)